NDAORALTABLET
Approved
Apr 1995
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
4
Data completeness
6/8 — Strong
HYZAAR (losartan potassium and hydrochlorothiazide) by Merck & Co. is [formed from angiotensin i in a reaction catalyzed by angiotensin converting enzyme (ace, kininase ii)], is a potent vasoconstrictor, the primary vasoactive hormone of the renin-angiotensin system and an important component in the pathophysiology of hypertension. Approved for hypertension, to lower blood pressure, stroke in patients with hypertension and 3 more indications. First approved in 1995.
Drug data last refreshed Yesterday · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HYZAAR is a fixed-dose combination of losartan potassium (an angiotensin II receptor antagonist) and hydrochlorothiazide (a thiazide diuretic) for oral treatment of hypertension. It reduces blood pressure by blocking angiotensin II vasoconstriction and promoting sodium/water excretion. The combination is indicated for hypertension, stroke prevention in hypertensive patients, and reduction of left ventricular hypertrophy.
$0.002BPart D
LOE ApproachingDeclining
Product is in late-stage lifecycle with declining Part D utilization; commercial teams are likely focused on market defense and managed care negotiations rather than growth initiatives.
Mechanism of Action
[formed from angiotensin I in a reaction catalyzed by angiotensin converting enzyme (ACE, kininase II)], is a potent vasoconstrictor, the primary vasoactive hormone of the renin-angiotensin system and an important component in the pathophysiology of hypertension. It also stimulates aldosterone…
Pharmacologic Class:
Thiazide Diuretic
Worked on HYZAAR at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.